Exciting News From the Cystic Fibrosis Drug Pipeline: Antimicrobials and CFTR Modulators

We have been beyond fortunate to see some really positive news coming from the Pipeline over the past couple of weeks and months. First, a potential breathtaking (science pun!) antimicrobial from Vast Therapeutics is looking to conquer chronic infection in cystic fibrosis. Vast Therapeutics is “a preclinical stage pharmaceutical company focused on delivering the power...
Continue reading...

We Are a Community of Individuals

A discussion in the comments on one of my Facebook posts from the other day highlighted an interesting (and often overlooked) part of the cystic fibrosis world – people have very different individual needs. Here are some of the comments: Ultimately the topic here is the ACA – Affordable Care Act (Obamacare). We’ll touch on...
Continue reading...

Bipartisan Bill Seeks To Incentivize Antimicrobial Development; NTM Continues to Spread in CF Community

We are in desperate need of new antimicrobials to combat the growing threat of drug resistant bacteria. I think the majority of the governments in industrialized nations recognize this threat and are finally starting to mobilize against it. As it currently stands, though, there is little incentive for drug makers to dive into the antibiotic...
Continue reading...